Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-controlled Study of Sleep Apnea Participants (SHARP) (P9-9.004)

To assess whether solriamfetol, a dopamine-norepinephrine reuptake inhibitor (DNRI) approved to improve wakefulness in adults with obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS), could improve memory performance, preclinically, and cognition in EDS from OSA, clinically.